Trinkler F, Hauri D
Urologische Klinik, Universitätsspital Zürich.
Helv Chir Acta. 1994 Dec;60(6):1081-5.
We report our experience in evaluating PSA-follow-up of patients treated with radical prostatectomy. Also PSA is the most sensitive available screening test for relapse after radical prostatectomy, it is not 100% specific for cancer relapse while this serum marker is not specific for prostate cancer. In our opinion, patients with biochemical relapse (PSA > 0.5 ng/l) should undergo an early restaging including biopsy of the anastomosis. In 57% of our patients with PSA > 1.0 ng/l two months after surgery we found clinical recurrence 27 months later on.
我们报告了我们在评估接受根治性前列腺切除术患者的PSA随访方面的经验。此外,虽然PSA是根治性前列腺切除术后复发最敏感的现有筛查试验,但对于癌症复发它并非100%特异,且这种血清标志物对前列腺癌也不特异。我们认为,生化复发(PSA>0.5 ng/l)的患者应尽早进行重新分期,包括吻合口活检。在我们术后两个月PSA>1.0 ng/l的患者中,57%在27个月后出现了临床复发。